XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.3
OTHER (INCOME)/EXPENSE, NET
 9 Months Ended
Sep. 30, 2024
Other Nonoperating Income (Expense) [Abstract]  
OTHER (INCOME)/EXPENSE, NET OTHER (INCOME)/EXPENSE, NET
Three Months Ended September 30,Nine Months Ended September 30,
Dollars in millions2024202320242023
Interest expense (Note 10)$505 $280 $1,451 $850 
Royalty and licensing income (Note 4)(180)(365)(532)(1,068)
Royalty income - divestiture (Note 4)
(284)(217)(820)(623)
Investment income(94)(107)(364)(304)
Litigation and other settlements (a)
— (61)71 (393)
Provision for restructuring (Note 6)78 141 558 321 
Integration expenses (Note 6)69 54 214 180 
Equity investment (gains)/losses (Note 9)
(12)— (221)213 
Acquisition expense (Note 4)
— — 50 — 
Intangible asset impairment
47 29 47 29 
Other(b)
105 (12)134 8 
Other (income)/expense, net
$234 $(258)$588 $(787)
(a)    Includes $90 million of income related to the Eisai collaboration termination incurred during the nine months ended September 30, 2024 and $400 million of income related to Nimbus' TYK2 program change of control provision incurred during the nine months ended September 30, 2023.
(b)    Includes pension settlement charges of $100 million during the three months ended September 30, 2024 and $119 million during the nine months ended September 30, 2024 incurred in connection with the termination of the Bristol-Myers Squibb Puerto Rico, Inc. Retirement Income pension plan.

Litigation and Other Settlements

BeiGene Settlement

In August 2023, BMS and BeiGene, Ltd. ("BeiGene") entered into an agreement that terminated all contractual relationships and settled all on-going disputes and claims between the parties, including those related to the Abraxane license and supply agreements and related arbitration proceedings that were previously disclosed. As part of this agreement, BMS agreed to transfer 23.3 million of BeiGene ordinary shares of common stock held under a share subscription agreement back to BeiGene resulting in $322 million of expense that was included in Other (income)/expense, net during the three and nine months ended September 30, 2023. The expense was determined based on the closing price of the shares on the date of the transfer.
AstraZeneca Settlement
In July 2023, BMS entered into an agreement with AstraZeneca to settle all outstanding claims between the parties in the CTLA-4 litigation and the two PD-L1 antibody litigations. AstraZeneca is to pay an aggregate of $560 million to BMS in four payments through September 2026, which would be subject to sharing arrangements with Ono and Dana-Farber. BMS's share is approximately $418 million, of which the net present value of $384 million was reflected in Other (income)/expense during the three and nine months ended September 30, 2023.